NCT04116073View on ClinicalTrials.gov

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 9, 2020

Primary Completion Date

August 6, 2024

Study Completion Date

December 3, 2024

Conditions
Pancreatic Cancer Non-resectablePancreatic Cancer Metastatic
Interventions
DRUG

INCMGA00012 (PD-1 antibody)

INCMGA00012 (PD-1 antibody): 500 mg, 30 min IV infusion on Day 1 of each cycle (every 28 days)

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER